Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

CRAI vs EXPO

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CRAI
CRA International, Inc.

Consulting Services

IndustrialsNASDAQ • US
Market Cap$999M
5Y Perf.+277.9%
EXPO
Exponent, Inc.

Consulting Services

IndustrialsNASDAQ • US
Market Cap$3.16B
5Y Perf.-13.5%

CRAI vs EXPO — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CRAI logoCRAI
EXPO logoEXPO
IndustryConsulting ServicesConsulting Services
Market Cap$999M$3.16B
Revenue (TTM)$752M$582M
Net Income (TTM)$55M$106M
Gross Margin22.7%40.1%
Operating Margin11.1%20.6%
Forward P/E18.5x31.2x
Total Debt$76M$83M
Cash & Equiv.$18M$222M

CRAI vs EXPOLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CRAI
EXPO
StockMay 20May 26Return
CRA International, … (CRAI)100377.9+277.9%
Exponent, Inc. (EXPO)10086.5-13.5%

Price return only. Dividends and distributions are not included.

Quick Verdict: CRAI vs EXPO

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CRAI leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Exponent, Inc. is the stronger pick specifically for profitability and margin quality and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
CRAI
CRA International, Inc.
The Growth Play

CRAI carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 9.3%, EPS growth 20.8%, 3Y rev CAGR 8.3%
  • 6.2% 10Y total return vs EXPO's 191.0%
  • Lower volatility, beta 0.73, Low D/E 35.6%, current ratio 0.92x
Best for: growth exposure and long-term compounding
EXPO
Exponent, Inc.
The Income Pick

EXPO is the clearest fit if your priority is income & stability and defensive.

  • Dividend streak 13 yrs, beta 0.89, yield 1.9%
  • Beta 0.89, yield 1.9%, current ratio 2.40x
  • 18.2% margin vs CRAI's 7.3%
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthCRAI logoCRAI9.3% revenue growth vs EXPO's 4.2%
ValueCRAI logoCRAILower P/E (18.5x vs 31.2x), PEG 0.86 vs 5.25
Quality / MarginsEXPO logoEXPO18.2% margin vs CRAI's 7.3%
Stability / SafetyCRAI logoCRAIBeta 0.73 vs EXPO's 0.89
DividendsEXPO logoEXPO1.9% yield, 13-year raise streak, vs CRAI's 1.3%
Momentum (1Y)CRAI logoCRAI-11.9% vs EXPO's -13.0%
Efficiency (ROA)EXPO logoEXPO13.7% ROA vs CRAI's 8.7%, ROIC 36.3% vs 22.3%

CRAI vs EXPO — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CRAICRA International, Inc.
FY 2025
Time-and-Materials Contract
82.6%$621M
Fixed-Price Contract
17.4%$131M
EXPOExponent, Inc.
FY 2025
Engineering And Other Scientific
84.9%$494M
Environmental And Health
15.1%$88M

CRAI vs EXPO — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLEXPOLAGGINGCRAI

Income & Cash Flow (Last 12 Months)

EXPO leads this category, winning 5 of 6 comparable metrics.

CRAI and EXPO operate at a comparable scale, with $752M and $582M in trailing revenue. EXPO is the more profitable business, keeping 18.2% of every revenue dollar as net income compared to CRAI's 7.3%. On growth, CRAI holds the edge at +11.6% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCRAI logoCRAICRA International…EXPO logoEXPOExponent, Inc.
RevenueTrailing 12 months$752M$582M
EBITDAEarnings before interest/tax$109M$125M
Net IncomeAfter-tax profit$55M$106M
Free Cash FlowCash after capex$19M$122M
Gross MarginGross profit ÷ Revenue+22.7%+40.1%
Operating MarginEBIT ÷ Revenue+11.1%+20.6%
Net MarginNet income ÷ Revenue+7.3%+18.2%
FCF MarginFCF ÷ Revenue+2.5%+21.0%
Rev. Growth (YoY)Latest quarter vs prior year+11.6%+7.8%
EPS Growth (YoY)Latest quarter vs prior year-8.7%+6.5%
EXPO leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

CRAI leads this category, winning 6 of 7 comparable metrics.

At 18.8x trailing earnings, CRAI trades at a 40% valuation discount to EXPO's 31.0x P/E. Adjusting for growth (PEG ratio), CRAI offers better value at 0.87x vs EXPO's 5.21x — a lower PEG means you pay less per unit of expected earnings growth.

MetricCRAI logoCRAICRA International…EXPO logoEXPOExponent, Inc.
Market CapShares × price$999M$3.2B
Enterprise ValueMkt cap + debt − cash$1.1B$3.0B
Trailing P/EPrice ÷ TTM EPS18.75x31.02x
Forward P/EPrice ÷ next-FY EPS est.18.52x31.24x
PEG RatioP/E ÷ EPS growth rate0.87x5.21x
EV / EBITDAEnterprise value multiple10.87x23.28x
Price / SalesMarket cap ÷ Revenue1.33x5.43x
Price / BookPrice ÷ Book value/share4.80x8.43x
Price / FCFMarket cap ÷ FCF53.86x25.85x
CRAI leads this category, winning 6 of 7 comparable metrics.

Profitability & Efficiency

EXPO leads this category, winning 5 of 8 comparable metrics.

CRAI delivers a 25.6% return on equity — every $100 of shareholder capital generates $26 in annual profit, vs $26 for EXPO. EXPO carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to CRAI's 0.36x. On the Piotroski fundamental quality scale (0–9), EXPO scores 6/9 vs CRAI's 5/9, reflecting solid financial health.

MetricCRAI logoCRAICRA International…EXPO logoEXPOExponent, Inc.
ROE (TTM)Return on equity+25.6%+25.5%
ROA (TTM)Return on assets+8.7%+13.7%
ROICReturn on invested capital+22.3%+36.3%
ROCEReturn on capital employed+26.9%+19.2%
Piotroski ScoreFundamental quality 0–956
Debt / EquityFinancial leverage0.36x0.21x
Net DebtTotal debt minus cash$58M-$139M
Cash & Equiv.Liquid assets$18M$222M
Total DebtShort + long-term debt$76M$83M
Interest CoverageEBIT ÷ Interest expense23.90x
EXPO leads this category, winning 5 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

CRAI leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in CRAI five years ago would be worth $19,067 today (with dividends reinvested), compared to $7,312 for EXPO. Over the past 12 months, CRAI leads with a -11.9% total return vs EXPO's -13.0%. The 3-year compound annual growth rate (CAGR) favors CRAI at 19.0% vs EXPO's -8.6% — a key indicator of consistent wealth creation.

MetricCRAI logoCRAICRA International…EXPO logoEXPOExponent, Inc.
YTD ReturnYear-to-date-23.6%-8.0%
1-Year ReturnPast 12 months-11.9%-13.0%
3-Year ReturnCumulative with dividends+68.5%-23.5%
5-Year ReturnCumulative with dividends+90.7%-26.9%
10-Year ReturnCumulative with dividends+619.1%+191.0%
CAGR (3Y)Annualised 3-year return+19.0%-8.6%
CRAI leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CRAI and EXPO each lead in 1 of 2 comparable metrics.

CRAI is the less volatile stock with a 0.73 beta — it tends to amplify market swings less than EXPO's 0.89 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXPO currently trades 78.4% from its 52-week high vs CRAI's 67.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCRAI logoCRAICRA International…EXPO logoEXPOExponent, Inc.
Beta (5Y)Sensitivity to S&P 5000.73x0.89x
52-Week HighHighest price in past year$227.29$81.95
52-Week LowLowest price in past year$142.99$63.25
% of 52W HighCurrent price vs 52-week peak+67.2%+78.4%
RSI (14)Momentum oscillator 0–10054.745.7
Avg Volume (50D)Average daily shares traded185K455K
Evenly matched — CRAI and EXPO each lead in 1 of 2 comparable metrics.

Analyst Outlook

EXPO leads this category, winning 2 of 2 comparable metrics.

Wall Street rates CRAI as "Buy" and EXPO as "Buy". Consensus price targets imply 32.4% upside for EXPO (target: $85) vs 27.1% for CRAI (target: $194). For income investors, EXPO offers the higher dividend yield at 1.87% vs CRAI's 1.35%.

MetricCRAI logoCRAICRA International…EXPO logoEXPOExponent, Inc.
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$194.00$85.00
# AnalystsCovering analysts18
Dividend YieldAnnual dividend ÷ price+1.3%+1.9%
Dividend StreakConsecutive years of raises913
Dividend / ShareAnnual DPS$2.06$1.20
Buyback YieldShare repurchases ÷ mkt cap+4.7%+3.1%
EXPO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

EXPO leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CRAI leads in 2 (Valuation Metrics, Total Returns). 1 tied.

Best OverallExponent, Inc. (EXPO)Leads 3 of 6 categories
Loading custom metrics...

CRAI vs EXPO: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is CRAI or EXPO a better buy right now?

For growth investors, CRA International, Inc.

(CRAI) is the stronger pick with 9. 3% revenue growth year-over-year, versus 4. 2% for Exponent, Inc. (EXPO). CRA International, Inc. (CRAI) offers the better valuation at 18. 8x trailing P/E (18. 5x forward), making it the more compelling value choice. Analysts rate CRA International, Inc. (CRAI) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CRAI or EXPO?

On trailing P/E, CRA International, Inc.

(CRAI) is the cheapest at 18. 8x versus Exponent, Inc. at 31. 0x. On forward P/E, CRA International, Inc. is actually cheaper at 18. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: CRA International, Inc. wins at 0. 86x versus Exponent, Inc. 's 5. 25x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — CRAI or EXPO?

Over the past 5 years, CRA International, Inc.

(CRAI) delivered a total return of +90. 7%, compared to -26. 9% for Exponent, Inc. (EXPO). Over 10 years, the gap is even starker: CRAI returned +619. 1% versus EXPO's +191. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CRAI or EXPO?

By beta (market sensitivity over 5 years), CRA International, Inc.

(CRAI) is the lower-risk stock at 0. 73β versus Exponent, Inc. 's 0. 89β — meaning EXPO is approximately 21% more volatile than CRAI relative to the S&P 500. On balance sheet safety, Exponent, Inc. (EXPO) carries a lower debt/equity ratio of 21% versus 36% for CRA International, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — CRAI or EXPO?

By revenue growth (latest reported year), CRA International, Inc.

(CRAI) is pulling ahead at 9. 3% versus 4. 2% for Exponent, Inc. (EXPO). On earnings-per-share growth, the picture is similar: CRA International, Inc. grew EPS 20. 8% year-over-year, compared to -1. 9% for Exponent, Inc.. Over a 3-year CAGR, CRAI leads at 8. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CRAI or EXPO?

Exponent, Inc.

(EXPO) is the more profitable company, earning 18. 2% net margin versus 7. 3% for CRA International, Inc. — meaning it keeps 18. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXPO leads at 20. 6% versus 11. 1% for CRAI. At the gross margin level — before operating expenses — EXPO leads at 25. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CRAI or EXPO more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, CRA International, Inc. (CRAI) is the more undervalued stock at a PEG of 0. 86x versus Exponent, Inc. 's 5. 25x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, CRA International, Inc. (CRAI) trades at 18. 5x forward P/E versus 31. 2x for Exponent, Inc. — 12. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EXPO: 32. 4% to $85. 00.

08

Which pays a better dividend — CRAI or EXPO?

All stocks in this comparison pay dividends.

Exponent, Inc. (EXPO) offers the highest yield at 1. 9%, versus 1. 3% for CRA International, Inc. (CRAI).

09

Is CRAI or EXPO better for a retirement portfolio?

For long-horizon retirement investors, CRA International, Inc.

(CRAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73), 1. 3% yield, +619. 1% 10Y return). Both have compounded well over 10 years (CRAI: +619. 1%, EXPO: +191. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CRAI and EXPO?

Both stocks operate in the Industrials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

CRAI

Stable Dividend Mega-Cap

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

EXPO

Income & Dividend Stock

  • Sector: Industrials
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 10%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CRAI and EXPO on the metrics below

Revenue Growth>
%
(CRAI: 11.6% · EXPO: 7.8%)
Net Margin>
%
(CRAI: 7.3% · EXPO: 18.2%)
P/E Ratio<
x
(CRAI: 18.8x · EXPO: 31.0x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.